Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05889182 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
A Phase 3 study of Hidradenitis Suppurativa, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,328
- Enrollment target
- 20
- Study locations
NCT05889182 is a Phase 3 study of Hidradenitis Suppurativa that is actively recruiting participants, run by AbbVie. The registered enrollment target is 1,328 participants, above the 573-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (132% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT05889182, a Phase 3 study of Hidradenitis Suppurativa, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,328 participants
- Enrollment target
- 20
- Study locations
Study Summary
Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (anal/genital) regions. This study will assess how safe and effective upadacitinib is in treating adult and adolescent participants with moderate to severe HS who have failed to respond to or are intolerant of anti-tumor necrosis factor (TNF) therapy. Adverse events and change in disease activity will be assessed. Upadacitinib is an approved drug for ulcerative colitis, atopic dermatitis, rheumatoid arthritis, psoriatic arthritis, and axial spondylarthritis and is being developed for the treatment of HS. This study is "double-blinded", meaning that neither the trial participants nor the study doctors will know who will be given upadacitinib and who will be given placebo. This study is comprised of 3 periods. In Period 1, participants are randomized into 2 groups called treatment arms where each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to placebo. In Period 2, participants are placed into 6 different groups depending on their placement and results in Period 1. Period 3 is the long-term extension period where participants will continue treatment from Period 2. Approximately 1328 adult and adolescent participants diagnosed with HS will be enrolled in approximately 300 sites worldwide. Participants will receive oral tablets of upadacitinib or placebo once daily for 36 weeks in Period 1 and Period 2. Eligible participants from Period 1 and Period 2 will enter Period 3 and receive oral tablets of upadacitinib or placebo once daily for 68 weeks. Participants will be followed up for approximately 30 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular outpatient visits during the study. The effect of the treatment will be checked by medical assessments, checking for side effects an
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Upadacitinib
Study Locations (20)
California
- Private Practice - Dr. Tooraj Raoof /ID# 254374 - Encino
- Marvel Clinical Research /ID# 276228 - Huntington Beach
- Dermatology Research Associates /ID# 254846 - Los Angeles
- NorCal Clinical Research /ID# 274219 - Rocklin
- Integrative Skin Science and Research /ID# 254930 - Sacramento
- University of California Davis Health /ID# 254229 - Sacramento
- Medderm Associates /ID# 253800 - San Diego
- Clinical Trials Research Institute /ID# 254466 - Thousand Oaks
Arizona
- Peak Dermatology Aesthetics and Wellness Fountain Hills /ID# 272564 - Fountain Hills
- Medical Dermatology Specialists /ID# 254226 - Phoenix
- Mayo Clinic - Scottsdale /ID# 254388 - Scottsdale
- Banner University Medicine Dermatology /ID# 255853 - Tucson
Arkansas
- Clinical Trials Institute - Northwest Arkansas /ID# 254924 - Fayetteville
- Burke Pharmaceutical Research /ID# 254238 - Hot Springs
- Arkansas Research Trials /ID# 254233 - North Little Rock
- NW Arkansas Clinical Trials Center /ID# 254311 - Rogers
Connecticut
- UConn Health Main /ID# 254507 - Farmington
- Yale University School of Medicine /ID# 254586 - New Haven
Alabama
- Cahaba Dermatology & Skin Health Center /ID# 254876 - Birmingham
Florida
- Skin Care Research Boca Raton /ID# 253814 - Boca Raton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,328 participants |
| Start Date | 2023-06-21 |
| Est. Completion | 2028-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05889182
The ClinicalTrials.gov registry entry for NCT05889182 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,328 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 573-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (132% higher). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05889182 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT05889182 about?
NCT05889182 is a clinical study titled "A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy". Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (anal/genital) regions. This study will assess how safe and effective upadacitinib is in treating adult and adolescent participants with moderate to sev...
What is the current status of trial NCT05889182?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,328 participants. The study started on 2023-06-21. Estimated completion is 2028-03.
What conditions does trial NCT05889182 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
What interventions are being tested in trial NCT05889182?
The interventions under investigation include: Placebo (DRUG), Upadacitinib (DRUG).
Who is sponsoring clinical trial NCT05889182?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05889182 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
RECRUITING · Phase 3
-
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
RECRUITING · Phase 3
-
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.